SCHEMBL3174689

SCHEMBL3174689

NC(=O)C=CCCc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 20/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16313909 1.00 GPR52 (0.66) GPR52
SCHEMBL3174683 1.00 GPR52 (0.66) GPR52
SCHEMBL9113431 0.89 GPR52 (0.53) GPR52
SCHEMBL10595578 0.87 GPR52 (0.56) GPR52
SCHEMBL10595585 0.87 GPR52 (0.56) GPR52
SCHEMBL2853636 0.84 GPR52 (0.70) GPR52
SCHEMBL2853640 0.84 GPR52 (0.70) GPR52
SCHEMBL2856224 0.84 GPR52 (0.70) GPR52
SCHEMBL6971328 0.82 GPR52 (0.68) GPR52
SCHEMBL9671273 0.81 GPR52 (0.66) GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109963843-A Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists 百时美施贵宝公司 2019-07-02 CN disclosed
WO-2018144869-A1 COMPOSITONS AND METHODS FOR MODULATING UBA5 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-08-09 WO disclosed
US-20170166516-A1 STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2017-06-15 US disclosed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 EP disclosed
WO-2016202808-A2 NEW SYNTHESIS OF TAPENTADOL-HCl INTERMEDIATES AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2016-12-22 WO disclosed
EP-3105203-A1 STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE AZAD Pharmaceutical Ingredients AG (CH) 2016-12-21 EP disclosed
WO-2015121265-A1 STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE AZAD PHARMACEUTICAL INGREDIENTS AG (CH) 2015-08-20 WO disclosed
US-8075937-B2 Alkyldienamides exhibiting taste and sensory effect in flavor compositions INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2011-12-13 US disclosed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP disclosed
US-20090311402-A1 ALKYLDIENAMIDES EXHIBITING TASTE AND SENSORY EFFECT IN FLAVOR COMPOSITIONS INTERNATIONAL FLAVORS & FRAGRANCES INC. 2009-12-17 US disclosed
US-7632531-B2 Alkyldienamides exhibiting taste and sensory effect in flavor compositions International Flavors & Fragnances Inc. (US) 2009-12-15 US disclosed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP disclosed
EP-1473287-B1 Alkyldienamides exhibiting taste and sensory effect in flavor compositions INT FLAVORS & FRAGRANCES INC (US) 2006-06-21 EP disclosed
EP-1473287-A2 Alkyldienamides exhibiting taste and sensory effect in flavor compositions INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2004-11-03 EP disclosed
US-20040202619-A1 Alkyldienamides exhibiting taste and sensory effect in flavor compositions INTERNATIONAL FLAVORS & FRAGRANCES INC. 2004-10-14 US disclosed
CN-1114834-A antidiabetic agent OTSUKA PHARMA CO LTD (JP) 1996-01-10 CN disclosed
EP-0670831-A1 QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-09-13 EP disclosed
WO-1995009159-A1 QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1995-04-06 WO disclosed
US-4948719-A NONFOGGING, NONDELAMINATING FUJI PHOTO FILM CO., LTD. (JP) 1990-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040202619-A1 Alkyldienamides exhibiting taste and sensory effect in flavor compositions TAS2R5, TAS2R4, TAS2R3 GPR52 1550/4885
US-20170166516-A1 STABLE POLYMORPH FORM B OF TAPENTADOL HYDROCHLORIDE CYP2D6, CYP2C9, CYP3A43 GPR52 1471/4885
US-20090311402-A1 ALKYLDIENAMIDES EXHIBITING TASTE AND SENSORY EFFECT IN FLAVOR COMPOSITIONS TAS2R5, TAS2R45, TAS2R16 GPR52 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.